Abstract
Background Monitoring safety outcomes following COVID-19 vaccination is critical for understanding vaccine safety especially when used in key populations such as elderly persons age 65 years and older who can benefit greatly from vaccination. We present new findings from a nationally representative early warning system that may expand the safety knowledge base to further public trust and inform decision making on vaccine safety by government agencies, healthcare providers, interested stakeholders, and the public.
Methods We evaluated 14 outcomes of interest following COVID-19 vaccination using the US Centers for Medicare & Medicaid Services (CMS) data covering 30,712,101 elderly persons. The CMS data from December 11, 2020 through Jan 15, 2022 included 17,411,342 COVID-19 vaccinees who received a total of 34,639,937 doses. We conducted weekly sequential testing and generated rate ratios (RR) of observed outcome rates compared to historical (or expected) rates prior to COVID-19 vaccination.
Findings Four outcomes met the threshold for a statistical signal following Pfizer-BioNTech vaccination including pulmonary embolism (PE; RR=1.54), acute myocardial infarction (AMI; RR=1.42), disseminated intravascular coagulation (DIC; RR=1.91), and immune thrombocytopenia (ITP; RR=1.44). After further evaluation, only the RR for PE still met the statistical threshold for a signal; however, the RRs for AMI, DIC, and ITP no longer did. No statistical signals were identified following vaccination with either the Moderna or Janssen vaccines.
Interpretation This early warning system is the first to identify temporal associations for PE, AMI, DIC, and ITP following Pfizer-BioNTech vaccination in the elderly. Because an early warning system does not prove that the vaccines cause these outcomes, more robust epidemiologic studies with adjustment for confounding factors, including age and nursing home residency, are underway to further evaluate these signals. FDA strongly believes the potential benefits of COVID-19 vaccination outweigh the potential risks of COVID-19 infection.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Hui-Lee Wong, Cindy Zhou, Deborah Thompson, Rositsa Dimova, Patricia Lloyd, Richard Forshee, and Steven Anderson are/were salaried employees of the U.S. Food and Drug Administration; Ellen Tworkoski, Mao Hu, Bradley Lufkin, Rose Do, Laurie Feinberg, Yoganand Chillarige, and Thomas MaCurdy are/were salaried employees of Acumen, LLC, which is a contractor with the U.S. Food and Drug Administration; Jeffrey Kelman is a salaried employee of the Centers for Medicare & Medicaid Services; Ellen Tworkoski is currently a salaried employee of Biogen, which includes stock options provided to her as part of employee benefits; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
The US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. The Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDA's Sentinel Initiative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Hui-Lee Wong, Cindy Zhou, Deborah Thompson, Rositsa Dimova, Patricia Lloyd, Richard Forshee, and Steven Anderson are/were salaried employees of the U.S. Food and Drug Administration; Ellen Tworkoski, Mao Hu, Bradley Lufkin, Rose Do, Laurie Feinberg, Yoganand Chillarige, and Thomas MaCurdy are/were salaried employees of Acumen, LLC, which is a contractor with the U.S. Food and Drug Administration; Jeffrey Kelman is a salaried employee of the Centers for Medicare & Medicaid Services; Ellen Tworkoski is currently a salaried employee of Biogen, which includes stock options provided to her as part of employee benefits; no other relationships or activities that could appear to have influenced the submitted work.
Data Availability
The study protocol was publicly posted as referenced in the manuscript before data analyses and related documents can be made available where needed, by contacting the corresponding author. De-identified participant data will not be shared without approval from CMS.
